Hellenic J Cardiol 2013; 54: 18-24
Original Research
The ATHENS TAVR Registry of Newer Generation
Transfemoral Aortic Valves: 30-Day Outcomes
Konstantinos spargias1,2, Konstantinos toutouzas3, Michael chrissoheris1,
andreas synetos3, antonis halapas1, ioannis paizis1, georgios latsios3,
Konstantinos stahogianis3, spyridon papaMetzelopoulos2, stavros zanos2,
gregory pavlides2, achileas zacharoulis4, aias antoniades4,
christodoulos stefanadis3
1
THV Department, Hygeia Hospital, 2First Cardiology Department, Onassis, CTC, 3Cardiology Department,
Hippokration Hospital, 4Cardiology Department, Attikon Hospital, Athens, Greece
Key words:
Aortic stenosis,
transcutaneous
aortic valve
implantation,
transfemoral aortic
valve implantation,
CoreValve, Edwards
SAPIEN.
Manuscript received:
October 18, 2011;
Accepted:
March 5, 2012.
Introduction: Transcatheter aortic valve replacement (TAVR) is a documented treatment for patients with
symptomatic aortic stenosis who are at very high or prohibitive operative risk. We sought to investigate the outcomes of transfemoral procedures with the newer generation valves in four TAVR centres in Athens, Greece.
Methods: The ATHENS TAVR Registry included all patients who underwent transfemoral implantation of the
newer generation valves in 4 Athens TAVR centres (self-expanding valve 67 patients, balloon-expandable
valve 59 patients). We present the procedural and echocardiographic data and the 30-day clinical outcomes
according to valve type.
Results: A total of 126 patients underwent 126 procedures (67 CoreValve, Medtronic; 59 SAPIEN XT, Edwards Lifesciences). The mean age and logistic EuroSCORE were 80 ± 8 years and 25 ± 13%. The procedural and device success rates were 100% and 98%, respectively. The 30-day mortality was 1% (n=1), the
major vascular event rates 9% (similar for both valve types), and a new permanent pacemaker was implanted more often during the same hospitalisation after CoreValve (33% vs. 9%, p=0.001). The mean effective
aortic valve area increased and the mean transvalvular pressure gradient declined post implantation (from
0.66 ± 0.15 cm2 to 1.61 ± 0.43 cm2, p<0.001; from 51 ± 14 mm Hg to 10 ± 3 mm Hg, p<0.001). The mean
grade of aortic insufficiency increased after CoreValve (from 1.2 ± 0.6 to 1.5 ± 0.7, p=0.03) but remained
stable after SAPIEN XT (1.0 ± 0.8 and 1.0 ± 0.6, p=0.88) implantation.
Conclusions: TAVR outcomes with both the newer generation transfemoral valves in the ATHENS Registry
were excellent. We observed a greater need for a new permanent pacemaker and a greater degree of aortic
valve insufficiency after CoreValve implantation.
Address:
Konstantinos Spargias
THV Department,
Hygeia Hospital
9 Red Cross St.
151 23 Athens, Greece
e-mail: spargias@hygeia.gr
T
ranscatheter aortic valve replacement (TAVR) has emerged as an
alternative to surgical aortic valve
replacement (SAVR) for patients with
symptomatic severe aortic stenosis who
are considered to be at very high or prohibitive operative risk.1-6 The PARTNER
randomised trials have demonstrated the
superiority of TAVR over standard medical treatment (including balloon valvuloplasty) in patients considered inoper-
18 • HJC (Hellenic Journal of Cardiology)
able due to prohibitive risk (Cohort B),
and the non-inferiority of TAVR compared to SAVR in high-risk patients accepted for both treatment approaches.1,2
Since their launch for clinical use in Europe, both available valves (CoreValve,
Medtronic, and SAPIEN XT, Edwards
Lifesciences) have undergone considerable technical enhancements aimed at improving clinical outcomes and making the
devices more operator-friendly. The SA-
ATHENS TAVR Registry
PIEN valve, for example, underwent numerous valve
and delivery system improvements to reach the currently used SAPIEN XT with the Novaflex+ delivery
system and the e-sheath (profile downsized from 2224 F to 16-18 F). Likewise, the CoreValve, which had
already downsized its profile to 18F earlier, has more
recently launched its new precision delivery catheter,
Accutrak. However, it will take some time to obtain
results from prospective clinical trials investigating
these latest generation devices. In the meantime, reports from the roll-out in the real-world environment
of these newer generation devices are valuable. The
objectives of this four-centre study were: 1) to evaluate the procedural, echocardiographic and 30-day
clinical outcomes of patients undergoing transfemoral implantation of the newer generation valves in the
“real world”; 2) to compare the procedural, echocardiographic and 30 day clinical outcomes of the nonrandomised use of the two available valve types.
Methods
All consecutive patients who underwent transfemoral TAVR performed by the authors using the newer
generation valves between October 2009 and September 2011 in 4 centres in Athens, Greece, were included.
The valves used were the CoreValve (requiring an 18
F sheath for both the 26 mm and 29 mm sizes, with or
without the precision delivery catheter Accutrak) and
the SAPIEN XT (requiring an 18 F sheath for the 23
mm and 19 F for the 26 mm size; and more recently the
Novaflex+ delivery system requiring the 16 F e-sheath
for the 23 mm and 18 F for the 26 mm size in 9 patients).
Patients considered eligible for TAVR underwent a systematic workup protocol that included Doppler echocardiography, coronary angiography, aortoiliofemoral
angiography, and quite often computed tomography.
All potential candidates for TAVR were evaluated by a
multidisciplinary team composed of interventional cardiologists and cardiac surgeons, who determined the eligibility of the patient for TAVR. In addition, all the patients’ medical files were evaluated and approved by a
government committee consisting of senior cardiologists
and cardiac surgeons.
Patients’ comorbidities were characterised according to the EuroSCORE and the STS risk score
definitions.7,8
Porcelain aorta was defined as extensive circumferential calcification of the thoracic aorta, as assessed by computed tomography and/or fluoroscopy.
Baseline and follow-up clinical and echocardiogra-
phy data were prospectively gathered in each participating centre. All patients provided written informed
consent to the procedures.
Procedures
The procedures were performed in a catheterisation
laboratory with operating-room–like sterile precautions. The personnel in the room in most instances
consisted of 2-3 interventional cardiologists, 1 cardiac surgeon, 1 cardiac anaesthesiologist, 1 cardiologist
echo specialist, 2 nurses and 1 valve technician.
All possible patient body entry sites were subjected to meticulous surgical scrubbing. Premedication
with aspirin and clopidogrel was given, and antibiotics were administered intravenously before the procedure according to local hospital practices. Heparin
50 U/kg IV was administered, targeted at an activated coagulation time of approximately 250 s just before valve implantation. Monitored anaesthesia care
or general anaesthesia was initiated according to local
practices and the medical requirements of each patient. Access to the common femoral artery suitable
for valve delivery, and to the contralateral femoral artery and vein was obtained. Preclosure with the Prostar XL system (Abbott Vascular, IL, USA) was performed in all procedures. Cardiac pacing was with a
transvenous wire in the right ventricle. Rapid pacing
capacity (usually 160-200 bpm) and the consequent
haemodynamic effect (aiming at a constant aortic
pressure <50 mmHg) were confirmed. Ascending
aortography was performed and the view that aligned
all three sinuses of Valsalva was used for optimal
valve positioning. Following valve implantation the
result was checked by angiography and echocardiography. Finally, the peripheral entry site was checked
by angiography after the Prostar closure.
Endpoints
For all clinical endpoints, the standardised definitions
for transcatheter aortic valve implantation in the consensus report from the Valve Academic Research
Consortium (VARC) were used.9 The clinical endpoints examined were total mortality, major vascular
and bleeding complications, any stroke and the need
for a new pacemaker at 30 days.
Echocardiography
Transthoracic and/or transoesophageal echocardiog(Hellenic Journal of Cardiology) HJC • 19
K. Spargias et al
raphy were performed prior to the procedure and
transthoracic echocardiography was performed prior
to hospital discharge and/or approximately 30 days
after the procedure. The last complete echocardiographic examination (the 30-day examination in 89%
and the examination prior to hospital discharge in
11% of patients) was considered for purposes of analysis. Transaortic flow was recorded with continuous
wave Doppler using a multi-window approach, transaortic gradients were calculated using the simplified
Bernoulli equation, and the effective aortic valve orifice was calculated by the continuity equation.10 Semiquantitative analysis based on the characteristics of
the regurgitant jet was used for assessment of valvular insufficiency and reported in grades 0 to 4.10 Retrospective application of the lately introduced VARC
criteria for aortic regurgitation was not feasible. All
echocardiographic imaging and analyses were performed locally by the same echocardiography teams.
The valve cover index was expressed as (prosthesis
diameter - TEE annulus diameter) / prosthesis diameter × 100.11
Continuous variables were analysed using the 2-sample independent or paired t-test, as appropriate. All
tests were 2-sided, and a significance level of 5% was
used. Statistical analyses were performed using SPSS
software (version 11.0.1, SPSS Inc, Chicago, Ill).
Results
A total of 126 patients underwent 126 procedures (67
CoreValve, Medtronic, MN, USA; 59 SAPIEN XT,
Edwards Lifesciences, CA, USA). Table 1 shows a
breakdown of the procedures performed by participating site and according to the valve type. Two of
the centres were using both valve types in a fairly balanced way, while the other two were exclusive users
of only one valve type (one CoreValve and one SAPIEN XT). The mean age and logistic EuroSCORE
were 80 ± 8 years and 25 ± 13%. The majority of
the patients treated were women (59%). Table 2 il-
Table 1. The Athens TAVR Registry: patients and valve types per
site.
All patients
Statistical analysis
Data are reported as mean ± SD for continuous variables and percentages for nominal variables. Explorative statistical methods were used to compare the
study groups according to the valve type implanted.
Hygeia Hospital
Hippokration Hospital
Onassis CTC
Attikon Hospital
Total
50
38
27
11
126
CoreValve SAPIEN XT
14
38
15
0
67
36
0
12
11
59
Table 2. Clinical and procedural characteristics.
CoreValve
n=67
Age years
Gender female, %
BMI, kg/m2
Logistic EuroSCORE
STS
STS m&m
NYHA class
LVEF
LOS (median), days
LOS ICU/CCU (median), days
AV annulus, mm
Anaesthesia MAC/GA, %
Fluoroscopy time, min
Valve diameter, mm
23/26/29 mm
Valve cover index
81 ± 7
51
26 ± 4
26 ± 14
7.0 ± 5.2
28.7 ± 13.4
2.9 ± 0.5
53 ± 8
5.4 ± 1.9 (5)
2.6 ± 1.5 (2)
22.5 ± 2.0
40/60
21.31 ± 5.03
27.4 ± 1.5
0/37/30
18 ± 6
SAPIEN XT
n=59
p
79 ± 9
68
27 ± 4
23 ± 12
9.1 ± 7.1
33.7 ± 18.3
3.1 ± 0.4
54 ± 11
7.3 ± 6.0 (5)
2.1 ± 2.1 (2)
20.7 ± 1.8
88/12
18.18 ± 6.43
23.8 ± 1.4
42/17/0
13 ± 4
0.14
0.07
0.06
0.18
0.21
0.29
0.04
0.75
0.02
0.12
<0.001
<0.001
0.10
<0.001
<0.001
BMI – body mass index; NYHA – New York Heart Association; LVEF – left ventricular ejection fraction; STS (m&m) – Society of Thoracic Surgeons
(mortality and morbidity); LOS – length of stay; ICU/CCU – intensive/coronary care unit; AV – aortic valve; MAC/GA – monitored anaesthesia care/
general anaesthesia.
20 • HJC (Hellenic Journal of Cardiology)
ATHENS TAVR Registry
lustrates the clinical and procedural characteristics of
the patients according to the valve type received. Patients treated with the SAPIEN XT had a worse functional class at baseline and their hospital stay was on
average 2 days longer. The latter was the result of 2
outliers with prolonged hospitalisations in the SAPIEN XT group (the median duration of the hospital
stay was 5 days for both valve types).
General anaesthesia was used more often in the
CoreValve procedures. The CoreValve patients had
on average 2 mm larger annuli than the SAPIEN XT
patients and the valve used was on average almost 4
mm larger in diameter. As a result the valve cover index was larger in the CoreValve patients.
Table 3 presents the echocardiographic data from
before and after the procedure. The effective aortic valve area increased and the mean transvalvular
pressure gradient declined post implantation in all
patients (from 0.65 ± 0.15 cm 2 to 1.58 ± 0.41 cm2,
p<0.001; from 50 ± 14 mm Hg to 10 ± 3 mm Hg,
p<0.001). There were no significant differences between the two valve-type groups at baseline and the
only significant difference after implantation was
more aortic insufficiency in the CoreValve group as
compared to the SAPIEN XT group (42% vs. 17%
had grade ≥2, p=0.004). The degree of aortic insufficiency increased after CoreValve (from grade 1.2
± 0.6 to 1.5 ± 0.7, p=0.03) but remained stable af-
ter SAPIEN XT (from grade 1.0 ± 0.8 to 1.0 ± 0.6,
p=0.88) implantation.
The procedural success rate was 100% and the
device success rate was 98% (due to the need for a
second valve in 2 patients). The 30-day mortality was
1% (1 patient who received a SAPIEN XT died at
day 5 due to aspiration pneumonia). Table 4 presents the 30-day clinical outcomes. The major vascular
event rate was 9% and the major bleeding event rate
was 2%, with similar occurrences for both valve types.
No stroke of any severity was observed. A new permanent pacemaker was implanted more often after
CoreValve implantation (33% vs. 9%, p=0.001).
Discussion
This multi-centre study of 126 patients with severe
symptomatic aortic stenosis at very high or prohibitive surgical risk shows that TAVR using the newer
generation transfemoral valves was associated with
a 30-day mortality of 1%, a stroke rate of 0%, and a
major vascular/bleeding event rate of 10%. These results compare favourably to other experiences from
trials and registries. The operative risk of these patients was substantial and not inferior to that reported in other series; thus, the excellent outcomes in our
registry cannot be attributed to a better patient substrate.1-6 We suggest that, apart from meticulous pa-
Table 3. Pre- and post-TAVR echocardiographic parameters.
CoreValve
n=67
SAPIEN XT
n=59
p
Pre-TAVR:
EAVO, cm2
Mean PG, mmHg
Max PG, mmHg
AVR grade
Grade ≥2, %
MVR grade
LVEF
PAP systolic, mmHg
0.67 ± 0.16
51 ± 15
87 ± 19
1.2 ± 0.6
22
1.2 ± 0.5
53 ± 8
49 ± 17
0.65 ± 0.15
52 ± 14
84 ± 22
1.0 ± 0.8
22
1.4 ± 0.9
54 ± 11
51 ± 15
0.37
0.78
0.44
0.13
1
0.21
0.75
0.64
Post-TAVR:
EAVO, cm2
Mean PG, mmHg
Max PG, mmHg
AVR grade
Grade ≥2, %
MVR grade
LVEF
PAP systolic, mmHg
1.57 ± 0.46
9±3
18 ± 6
1.5 ± 0.7
44
1.3 ± 0.5
55 ± 8
40 ± 11
1.67 ± 0.38
11 ± 4
20 ± 8
1.0 ± 0.6
17
1.3 ± 0.8
57 ± 10
46 ± 13
0.36
0.06
0.21
<0.001
0.003
0.63
0.42
0.23
EAVO – effective aortic valve orifice; PG – pressure gradient; A(M)VR – aortic (mitral) valve regurgitation; LVEF – left ventricular ejection fraction; PAP
– pulmonary artery pressure.
(Hellenic Journal of Cardiology) HJC • 21
K. Spargias et al
Table 4. Thirty-day clinical outcomes.
Total
n=126
Mortality, n(%)
Procedure success, n(%)
Device success, n(%)
Major vascular events, n(%)
Major bleeding events, n(%)
Stroke (any), n(%)
New pacemaker, n(%)
1
126
124
11
2
0
27
(1)
(100)
(98)
(9)
(2)
(0)
(21)
tient screening and selection, the newer generation
devices used in all our patients offer the best explanation for these excellent outcomes.
The most notable improvement in the newer generation devices is the significant reduction of the system profile from well above 20 F to 16-19 F. This certainly made the accomplishment of vascular access
easier and expanded the patient population suitable
for transfemoral implantation. Indeed, one recent
study demonstrated a threefold reduction in major
vascular events when the newer generation SAPIEN
XT valve with the Novaflex delivery system (18-19F)
was used as compared with the older SAPIEN valve
(22-24 F).12
The standardised endpoint definitions for transcatheter aortic valve implantation clinical trials were
published in January 2011; therefore, attempting
comparisons of clinical outcomes among previous reports is not possible without applying non-uniform
criteria. In recent reports applying the VARC definitions, the major vascular event rates using older-generation transfemoral valves were double-digit figures
and varied from 15.7% to 33.3%.12-14 The major vascular event rate, according to VARC definitions, in
our registry was 9%, while the only other registries
that reported on the newer generation transfemoral
valves quoted rates of 11.1% and 13%.12,15 It is reasonable to expect lower vascular event rates with the
use of lower profile devices, provided that they are
used sensibly and not aggressively by pushing the limits in patients with borderline vascular access. In any
case, attention to detail is always required and the
value of meticulous vascular screening should be underscored.
The self-expanding and balloon-expandable
valves were almost equally used and the baseline clinical characteristics of these patient groups were similar. In addition to comparable surgical risk, they had
comparable aortic stenosis severity and similar left
22 • HJC (Hellenic Journal of Cardiology)
CoreValve
n=67
1
67
66
5
0
0
22
(1)
(100)
(98)
(8)
(0)
(0)
(33)
SAPIEN XT
n=59
0
59
58
6
2
0
5
(0)
(100)
(98)
(10)
(3)
(0)
(9)
p
1
1
1
0.75
0.22
1
0.001
ventricular systolic function, degrees of aortic and mitral regurgitation, and pulmonary artery systolic pressures at baseline. Patients implanted with the self-expanding valve had on the average larger annuli and
received larger valves, reflecting the coverage of the
upper range annulus diameters by this valve. This
inherent difference between the two valves also resulted in the use of larger-diameter valvuloplasty balloons and the attainment of a larger valve-cover index with the self-expanding valve. However, these did
not translate into a larger effective valve orifice or reduced aortic valve insufficiency with the self-expanding valve post implantation. On the contrary, the average grade of aortic valve insufficiency post implantation was significantly larger with the self-expanding
valve as compared to the balloon-expandable valve.
In this respect, it is interesting to note that, while the
degree of aortic insufficiency remained unchanged after implantation of the balloon-expandable valve, it
increased significantly after the implantation of the
self-expanding valve.
The degree of post-implantation aortic regurgitation is predictive of in-hospital, 30-day and 1-year
mortality,16,17 and in a recent meta-analysis deaths
at 30 days related to severe aortic regurgitation occurred only after implantation of the self-expanding
valve.18 Similarly to our findings, the recently presented German Registry reported a significantly higher
occurrence of high grade aortic regurgitation in patients implanted with the self-expanding as compared
to the balloon-expandable valve (grade ≥2 in 17% vs.
8%).17 Our patients appeared to have more aortic regurgitation from the outset (20% had grade ≥2) and,
while this proportion remained essentially unchanged
after implantation of the balloon-expandable valve,
it doubled after implantation of the self-expanding
valve.
The use of the two valve types in our registry was
not randomised, and moreover two of the four partici-
ATHENS TAVR Registry
pating centres were using only one of the two available
transcatheter valves (single valve programs). Therefore
any comparison of the echocardiographic data and the
procedural and clinical outcomes according to the type
of valve implanted in our registry can only be descriptive and should not be interpreted otherwise.
Although this study has all the shortcomings of a
registry, its value lies in the large number of patients
recruited from a country with no previous sizeable
registry reports on TAVR outcomes. The adverse
clinical events were not centrally adjudicated; however the application of the standardised VARC definitions should result in trustworthy self-reporting.
Similarly, the echocardiographic assessments were
not done by a core laboratory but locally and the standardised definitions for the prosthetic valve performance were not used. However, the facts that all the
examinations were done by the same investigators
and that paired examinations of each patient were
evaluated adds value to our findings.
Despite favourable surgical outcomes in many
elderly patients, the 30-day mortality rate in the top
10% risk range patients undergoing SAVR is 18.8%,
which is almost 5% higher than the expected rate
based on the Society for Thoracic Surgery (STS) riskscoring system. 19,20 These high-risk patients often
have significant comorbidities that limit their chance
for survival, such as obstructive pulmonary disease,
renal insufficiency, liver disease, reduced left ventricular function, previous coronary artery bypass surgery
or chest wall radiation. Apart from these high-risk
patients who do receive SAVR with a high predicted
mortality risk, it is estimated that for approximately
every 2 patients undergoing SAVR there is an additional patient who is judged to have prohibitive surgical risk by primary care physicians or general cardiologists and is not even offered SAVR.21
A number of risk scores have been used to predict the risk of patients considered for SAVR. In assessing the surgical risk of high risk patients, the logistic EuroSCORE tends to overestimate the surgical
risk (by up to a factor of 3),22 and the STS risk score
tends to slightly underestimate the procedural risk.19
In addition, these conventional risk scores do not
take into account a number of contraindications to
conventional SAVR, including porcelain aortas and
extreme frailty, as judged by the consulting surgeon.
To date, the first and only available randomised
data on TAVR comes from the PARTNER trials, in
which the first-generation SAPIEN valve (profile 2224 F) was tested. In the PARTNER B trial, 358 inop-
erable patients with severe, symptomatic aortic stenosis were randomised to transfemoral TAVR or standard medical therapy.2 The superiority of TAVR was
indisputably proved, since the primary endpoint of
death at 1 year was reduced by 45% and the number
needed to treat was just 5 patients. In the PARTNER
A trial, 699 patients with severe, symptomatic stenosis
at a high but not prohibitive surgical risk (logistic EuroSCORE>15%) were randomised to TAVR (stratified to transfemoral or transapical according to suitability) or SAVR.1 The non-inferiority of TAVR as
compared to SAVR was proved in this population. In
particular, the 1-year mortality in the transfemorally
treated patients was 4.2% lower than in their surgically treated counterparts. Since these results were announced, it has been accepted that TAVR should be
the standard of care for inoperable patients, and an
acceptable (non-inferior) alternative to SAVR in selected high-risk operable patients.
The ability to perform TAVR has transformed the
treatment paradigm in symptomatic patients with severe aortic stenosis, particularly in those who are inoperable or at high risk for SAVR. Future technical
developments will include further reducing the device
profile, enhancing device positioning and retrievability,
and promoting valve durability with anti-calcification
treatments. When coupled with evidence from sound
ongoing and future clinical trials, it is likely that TAVR
usage will be consolidated further in inoperable patients and its value as an alternative to SAVR may expand to include more selected high risk patients.
In conclusion, the ATHENS TAVR registry demonstrated excellent 30-day clinical outcomes and an
impressively low mortality of 1% with the use of the
newer generation transfemoral valves. Our clinical
outcomes compare favourably to those reported in
other series and clinical trials, all of which used the
older generation, larger profile transfemoral systems. The observational comparison of the two available valves in our registry showed similar clinical outcomes and differences that mostly reflect the CoreValve’s suitability for larger aortic valve annuli and its
greater impact on the conduction system. Our finding
of increased aortic valve regurgitation following the
self-expanding valve implantation merits further investigation within a randomised trial.
References
1. Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve re(Hellenic Journal of Cardiology) HJC • 23
K. Spargias et al
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
placement in high-risk patients. N Engl J Med. 2011; 364:
2187-2198.
Leon MB, Smith CR, Mack M, et al. Transcatheter aorticvalve implantation for aortic stenosis in patients who cannot
undergo surgery. N Engl J Med. 2010; 363: 1597-1607.
Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day
outcomes following transcatheter aortic valve implantation
using the third generation (18 Fr) corevalve revalving system:
results from the multicentre, expanded evaluation registry
1-year following CE mark approval. EuroIntervention. 2008;
4: 242-249.
Thomas M, Schymik G, Walther T, et al. One-year outcomes
of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry
of transcatheter aortic valve implantation using the Edwards
SAPIEN valve. Circulation. 2011; 124: 425-433.
Buellesfeld L, Gerckens U, Schuler G, et al. 2-year follow-up
of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Coll Cardiol. 2011; 57: 1650-1657.
Lefèvre T, Kappetein AP, Wolner E, et al. One year followup of the multi-centre European PARTNER transcatheter
heart valve study. Eur Heart J. 2011; 32: 148-157.
Nashef SAM, Roques F, Michel P et al. European system for
cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999; 16: 9-13.
O’Brien SM, Shahian DM, Filardo G, et al. The Society of
Thoracic Surgeons 2008 cardiac surgery risk models: part 2—
isolated valve surgery. Ann Thorac Surg. 2009; 88: S23-42.
Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint
definitions for transcatheter aortic valve implantation clinical
trials: a consensus report from the Valve Academic Research
Consortium. Eur Heart J. 2011; 32: 205-217.
Zoghbi WA, Enriquez-Sarano M, Foster E, et al; American
Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16: 777-802.
Détaint D, Lepage L, Himbert D, et al. Determinants of significant paravalvular regurgitation after transcatheter aortic
valve: implantation impact of device and annulus discongruence. JACC Cardiovasc Interv. 2009; 2: 821-827.
Mussardo M, Latib A, Chieffo A, et al. Periprocedural and
24 • HJC (Hellenic Journal of Cardiology)
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
short-term outcomes of transfemoral transcatheter aortic valve
implantation with the Sapien XT as compared with the Edwards Sapien valve. JACC Cardiovasc Interv. 2011; 4: 743-750.
Buchanan GL, Chieffo A, Montorfano M, et al. The role of
sex on VARC outcomes following transcatheter aortic valve
implantation with both Edwards SAPIEN™ and Medtronic
CoreValve ReValving System® devices: the Milan registry.
EuroIntervention. 2011; 7: 556-563.
Hayashida K, Lefèvre T, Chevalier B, et al. Transfemoral
aortic valve implantation new criteria to predict vascular
complications. JACC Cardiovasc Interv. 2011; 4: 851-858.
Van Mieghem NM, Nuis RJ, Piazza N, et al. Vascular complications with transcatheter aortic valve implantation using
the 18 Fr Medtronic CoreValve System: the Rotterdam experience. EuroIntervention. 2010; 5: 673-679.
Tamburino C, Capodanno D, Ramondo A, et al. Incidence
and predictors of early and late mortality after transcatheter
aortic valve implantation in 663 patients with severe aortic
stenosis. Circulation. 2011; 123: 299-308.
Abdel-Wahab M, Zahn R, Horack M, et al. Aortic regurgitation after transcatheter aortic valve implantation: incidence
and early outcome. Results from the German transcatheter
aortic valve interventions registry. Heart. 2011; 97: 899-906.
Moreno R, Calvo L, Salinas P, et al. Causes of peri-operative mortality after transcatheter aortic valve implantation:
a pooled analysis of 12 studies and 1223 patients. J Invasive
Cardiol. 2011; 23: 180-184.
Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL,
Mack MJ. Reliability of risk algorithms in predicting early
and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2008;
135: 180-187.
Litmathe J, Feindt P, Kurt M, Gams E, Boeken U. Aortic
valve replacement in octogenarians: outcome and predictors
of complications. Hellenic J Cardiol. 2011; 52: 211-215.
Brown ML, Schaff HV, Sarano ME, et al. Is the European
System for Cardiac Operative Risk Evaluation model valid
for estimating the operative risk of patients considered for
percutaneous aortic valve replacement? J Thorac Cardiovasc
Surg. 2008; 136: 566-571.
Iung B, Cachier A, Baron G, et al. Decision-making in elderly
patients with severe aortic stenosis: why are so many denied
surgery? Eur Heart J. 2005; 26: 2714-2720.